Osteopontin nanoparticle system for drug delivery

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 9/51 (2006.01) A61K 38/19 (2006.01)

Patent

CA 2730841

The present invention relates to nanoparticles comprising osteopontin and a polymer carrier, preferably a cationic carrier. Preferably, the cationic carrier is chitosan. Osteopontin and/or the cationic carrier may have bioactivity and/or the nanopar- ticle may comprise an additional component with bioactivity. Such additional bioactive component may e.g. be a siRNA. The nanoparticles of the invention may be used for treatment of bone diseases or inflammatory diseases.

L'invention concerne des nanoparticules comprenant de l'osthéopontine, et un support polymère, de préférence un support cationique. De préférence, le support cationique est du chitosane. L'osthéopontine et/ou le support cationique peuvent présenter une bioactivité et/ou la nanoparticule peut comprendre un constituant supplémentaire présentant une bioactivité. Un tel constituant supplémentaire bioactif peut être par exemple un ARNsi. Les nanoparticules de l'invention peuvent servir à traiter des maladies osseuses ou des maladies inflammatoires.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Osteopontin nanoparticle system for drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Osteopontin nanoparticle system for drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteopontin nanoparticle system for drug delivery will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1534702

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.